311 related articles for article (PubMed ID: 8082525)
1. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
Hoffmann J; Spengler M
Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
Hoffmann J; Spengler M
Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
[TBL] [Abstract][Full Text] [Related]
3. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
Hanefeld M; Fischer S; Schulze J; Spengler M; Wargenau M; Schollberg K; Fücker K
Diabetes Care; 1991 Aug; 14(8):732-7. PubMed ID: 1954810
[TBL] [Abstract][Full Text] [Related]
5. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
[TBL] [Abstract][Full Text] [Related]
6. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.
Costa B; Piñol C
Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Segal P; Feig PU; Schernthaner G; Ratzmann KP; Rybka J; Petzinna D; Berlin C
Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.
Kelley DE; Bidot P; Freedman Z; Haag B; Podlecki D; Rendell M; Schimel D; Weiss S; Taylor T; Krol A; Magner J
Diabetes Care; 1998 Dec; 21(12):2056-61. PubMed ID: 9839094
[TBL] [Abstract][Full Text] [Related]
9. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
Rosenstock J; Brown A; Fischer J; Jain A; Littlejohn T; Nadeau D; Sussman A; Taylor T; Krol A; Magner J
Diabetes Care; 1998 Dec; 21(12):2050-5. PubMed ID: 9839093
[TBL] [Abstract][Full Text] [Related]
11. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group.
Chan JC; Chan KW; Ho LL; Fuh MM; Horn LC; Sheaves R; Panelo AA; Kim DK; Embong M
Diabetes Care; 1998 Jul; 21(7):1058-61. PubMed ID: 9653595
[TBL] [Abstract][Full Text] [Related]
12. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
Coniff RF; Shapiro JA; Seaton TB; Bray GA
Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
[TBL] [Abstract][Full Text] [Related]
13. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study.
Hotta N; Kakuta H; Sano T; Matsumae H; Yamada H; Kitazawa S; Sakamoto N
Diabet Med; 1993 Mar; 10(2):134-8. PubMed ID: 8458189
[TBL] [Abstract][Full Text] [Related]
14. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.
Josse RG
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S167-72. PubMed ID: 8529510
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment.
Leonhardt W; Hanefeld M; Fischer S; Schulze J; Spengler M
Arzneimittelforschung; 1991 Jul; 41(7):735-8. PubMed ID: 1772463
[TBL] [Abstract][Full Text] [Related]
16. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes.
Hanefeld M; Haffner SM; Menschikowski M; Koehler C; Temelkova-Kurktschiev T; Wildbrett J; Fischer S
Diabetes Res Clin Pract; 2002 Mar; 55(3):221-7. PubMed ID: 11850098
[TBL] [Abstract][Full Text] [Related]
17. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients.
Fischer S; Patzak A; Rietzsch H; Schwanebeck U; Köhler C; Wildbrett J; Fuecker K; Temelkova-Kurktschiev T; Hanefeld M
Diabetes Obes Metab; 2003 Jan; 5(1):38-44. PubMed ID: 12542723
[TBL] [Abstract][Full Text] [Related]
18. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
Rosak C; Haupt E; Walter T; Werner J
Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
[TBL] [Abstract][Full Text] [Related]
19. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44).
Holman RR; Cull CA; Turner RC
Diabetes Care; 1999 Jun; 22(6):960-4. PubMed ID: 10372249
[TBL] [Abstract][Full Text] [Related]
20. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.
Bayraktar M; Van Thiel DH; Adalar N
Diabetes Care; 1996 Mar; 19(3):252-4. PubMed ID: 8742572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
